42
Participants
Start Date
September 30, 2014
Primary Completion Date
January 31, 2015
Study Completion Date
January 31, 2015
semaglutide
Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).
semaglutide
Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL) or intravenously (i.v.) (1mg/mL).
Berlin
Lead Sponsor
Novo Nordisk A/S
INDUSTRY